

Atara Biotherapeutics Inc (ATRA) - Financial and Strategic SWOT Analysis Review

https://marketpublishers.com/r/A0C7D9ED76E8EN.html

Date: September 2021 Pages: 53 Price: US\$ 125.00 (Single User License) ID: A0C7D9ED76E8EN

Abstracts

Atara Biotherapeutics Inc (ATRA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.



Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Atara Biotherapeutics Inc (Atara) is a biopharmaceutical company that develops T-cell based immunotherapies for the treatment of cancers, other autoimmune diseases, and severe viral infections. The company is evaluating its lead candidate, tabelecleucel in Phase III clinical trials for the treatment of epstein-barr virus associated post-transplant lymphoproliferative disorder (EBV+ PTLD) following hematopoietic cell transplant and solid organ transplant in patients who refracted rituximab. Its pipeline product candidates that are being developed for multiple indications in various stages of clinical trials include ATA188, ATA2271, ATA3219, ATA3271 and other CAR T programs. Atara is headquartered in San Francisco, California, the US.

Atara Biotherapeutics Inc Key Recent Developments

Aug 09,2021: Atara Biotherapeutics Appoints Cell Therapy and Oncology Commercialization Veteran Ameet Mallik to the Board of Directors Aug 09,2021: Atara Biotherapeutics Announces Second Quarter 2021 Financial Results and Operational Progress Aug 02,2021: Atara Biotherapeutics to Announce Second Quarter 2021 Financial Results on Monday, August 9, 2021



May 10,2021: Atara Biotherapeutics Names Cell Therapy & Oncology Leader Cokey Nguyen, Ph.D. as Chief Scientific Officer May 04,2021: Atara Biotherapeutics Announces First Quarter 2021 Financial Results and Operational Progress

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.



Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Contents

SECTION 1 - ABOUT THE COMPANY

Atara Biotherapeutics Inc - Key Facts Atara Biotherapeutics Inc - Key Employees Atara Biotherapeutics Inc - Key Employee Biographies Atara Biotherapeutics Inc - Major Products and Services Atara Biotherapeutics Inc - History Atara Biotherapeutics Inc - Company Statement Atara Biotherapeutics Inc - Locations And Subsidiaries Head Office Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview Atara Biotherapeutics Inc - Business Description R&D Overview Atara Biotherapeutics Inc - Corporate Strategy Atara Biotherapeutics Inc - SWOT Analysis SWOT Analysis - Overview Atara Biotherapeutics Inc - Strengths Atara Biotherapeutics Inc - Weaknesses Atara Biotherapeutics Inc - Opportunities Atara Biotherapeutics Inc - Threats Atara Biotherapeutics Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios Financial Ratios - Annual Ratios Performance Chart Financial Performance Financial Ratios - Interim Ratios Financial Ratios - Ratio Charts

SECTION 4 – COMPANY'S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES



Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

Atara Biotherapeutics Inc, Recent Deals Summary

SECTION 5 – COMPANY'S RECENT DEVELOPMENTS

Aug 09, 2021: Atara Biotherapeutics Appoints Cell Therapy and Oncology

Commercialization Veteran Ameet Mallik to the Board of Directors

Aug 09, 2021: Atara Biotherapeutics Announces Second Quarter 2021 Financial Results and Operational Progress

Aug 02, 2021: Atara Biotherapeutics to Announce Second Quarter 2021 Financial Results on Monday, August 9, 2021

May 10, 2021: Atara Biotherapeutics Names Cell Therapy & Oncology Leader Cokey Nguyen, Ph.D. as Chief Scientific Officer

May 04, 2021: Atara Biotherapeutics Announces First Quarter 2021 Financial Results and Operational Progress

Mar 09, 2021: Atara Biotherapeutics to Participate in Virtual 33rd Annual ROTH Conference

Mar 01, 2021: Atara Biotherapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Operational Progress

Feb 18, 2021: Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on Monday, March 1, 2021

Feb 08, 2021: Atara Biotherapeutics presents key data for advancing the development of Tab-cel and ATA188 at the 2021 Transplantation & Cellular Therapy Meeting digital experience

Jan 10, 2021: Atara Biotherapeutics will present recent advancements and key upcoming milestones at the 39th Annual J.P. Morgan Healthcare conference

SECTION 6 – APPENDIX

Methodology Ratio Definitions About GlobalData Contact Us Disclaimer



List Of Tables

LIST OF TABLES

Atara Biotherapeutics Inc, Key Facts Atara Biotherapeutics Inc, Key Employees Atara Biotherapeutics Inc, Key Employee Biographies Atara Biotherapeutics Inc, Major Products and Services Atara Biotherapeutics Inc, History Atara Biotherapeutics Inc, Other Locations Atara Biotherapeutics Inc, Subsidiaries Atara Biotherapeutics Inc, Key Competitors Atara Biotherapeutics Inc, Ratios based on current share price Atara Biotherapeutics Inc, Annual Ratios Atara Biotherapeutics Inc, Annual Ratios (Cont...1) Atara Biotherapeutics Inc, Interim Ratios Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021 Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021 Atara Biotherapeutics Inc, Recent Deals Summary **Currency Codes Capital Market Ratios Equity Ratios Profitability Ratios** Cost Ratios Liquidity Ratios Leverage Ratios **Efficiency Ratios**



List Of Figures

LIST OF FIGURES

Atara Biotherapeutics Inc, Performance Chart (2016 - 2020)

Atara Biotherapeutics Inc, Ratio Charts

Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021



I would like to order

Product name: Atara Biotherapeutics Inc (ATRA) - Financial and Strategic SWOT Analysis Review Product link: <u>https://marketpublishers.com/r/A0C7D9ED76E8EN.html</u>

Price: US\$ 125.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: <u>info@marketpublishers.com</u>

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/A0C7D9ED76E8EN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970